Diagnostics in China
China Medical Technologies broadens its in vitro diagnostic market presence in China through the purchase of Beijing Bio-Ekon Biotechnology for $28.8 million, announced Nov. 26. The acquired firm offers enzyme-linked immunosorbent assays and semi-automatic, enhanced chemiluminescence immunoassay (ECLIA) analyzers and related reagents in China, and expects to seek approval in China next year for a fully automatic version. CMT, which also offers ECLIA products, acquired fluorescent in situ hybridization diagnostics technology in February (1"The Gray Sheet" Feb. 12, 2007, p. 8)
More from Archive
More from Medtech Insight
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.